Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study

Journal of Psychosomatic Research

Volumn 74, Issue 1, 2013, Pages 57-63

  Loftis, Jennifer M ^a,b   Patterson, Alexander L ^a   Wilhelm, Clare J ^a,b   McNett, Henry ^a,b   Morasco, Benjamin J ^a,b   Huckans, Marilyn ^a,b   Morgan, Timothy ^c   Saperstein, Shira ^c   Asghar, Aliya ^c   Hauser, Peter ^d  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d VISN 22 Network Office   (United States)

Author keywords

Cytokines; Depression; Fatigue; Hepatitis C; Interferon alpha; Pain; Serotonin

Indexed keywords

CYTOKINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APPETITE DISORDER; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITIVE AFFECTIVE FACTOR SCORE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEPATITIS C; HUMAN; IRRITABILITY; MALE; PROSPECTIVE STUDY; PSYCHOSOMATIC DISORDER; SIDE EFFECT; TREATMENT OUTCOME; VETERAN;

ADULT; ANTIVIRAL AGENTS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; SEROTONIN; SOMATOFORM DISORDERS; TUMOR NECROSIS FACTOR-ALPHA; VETERANS;

EID: 84871673905     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2012.10.012     Document Type: Article

References (57)

1. Group TGBoHCW Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004, 44:20-29.
2. Seeff LB, Hoofnagle JH Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003, 7:261-287.
3. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000, 49:311-317.
4. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006, 44:491-498.
5. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, Kunik ME, Satrom SL, El-Serag HB Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol 2005, 39:731-736.
6. Dieperink E, Willenbring M, Ho SB Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867-876.
7. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
8. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007, 63:131-135.
9. Loftis JM, Hauser P The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004, 82:175-190.
10. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004, 38:530-534.
11. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010, 52:430-435.
12. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987, 147:1577-1580.
13. Capuron L, Ravaud A Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999, 340:1370.
14. Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res March 2011, 31(3):331-336.
15. Taylor MW, Feng GS Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991, 5:2516-2522.
16. Loftis JM, Morasco BJ, Menasco D, Fuchs D, Strater M, Hauser P Serum serotonin levels are associated with antiviral therapy outcomes in patients with chronic hepatitis C. Open Infect Dis J 2010, 4:132-141.
17. Schafer A, Scheurlen M, Seufert J, Keicher C, Weissbrich B, Rieger P, et al. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. J Hepatol 2010, 52:10-15.
18. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002, 22:86-90.
19. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7:468-473.
20. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001, 105:45-55.
21. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, et al. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol 2008, 103:2766-2775.
22. Russo S, Kema IP, Haagsma EB, Boon JC, Willemse PH, den Boer JA, et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med 2005, 67:773-777.
23. Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, Kruit WH, et al. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status. Psychiatry Clin Neurosci 2008, 62:597-602.
24. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10:538-544.
25. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007, 81:3662-3666.
26. Katafuchi T, Kondo T, Take S, Yoshimura M Enhanced expression of brain interferon-alpha and serotonin transporter in immunologically induced fatigue in rats. Eur J Neurosci 2005, 22:2817-2826.
27. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000, 10:129-132.
28. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:899-905.
29. Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. J Viral Hepat 2011, 18:e284-e291.
30. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006, 60:77-79.
31. Schmidt HD, Shelton RC, Duman RS Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011, 36:2375-2394.
32. Patterson AL, Morasco BJ, Fuller BE, Indest DW, Loftis JM, Hauser P Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?. Gen Hosp Psychiatry 2011, 33:354-362.
33. Alexopoulos GS Depression in the elderly. Lancet 2005, 365:1961-1970.
34. Fountoulakis KN, O'Hara R, Iacovides A, Camilleri CP, Kaprinis S, Kaprinis G, et al. Unipolar late-onset depression: a comprehensive review. Ann Gen Hosp Psychiatry 2003, 2:11.
35. First MB, Spitzer RL, Gibbon M, Williams JBW Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
36. Beck AT, Steer RA, Brown GK Manual for the Beck Depression Inventory-II 1996, Psychological Corp., San Antonio (TX).
37. Valentine AD, Meyers CA, Talpaz M Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995, 13:561-566.
38. Kumar G, Steer RA, Teitelman KB, Villacis L Effectiveness of Beck Depression Inventory-II subscales in screening for major depressive disorders in adolescent psychiatric inpatients. Assessment 2002, 9:164-170.
39. Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics 2011, 52:433-440.
40. Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-alpha and ribavirin therapy: a prospective evaluation. Am J Gastroenterol 2011, 106:2123-2132.
41. Loftis JM, Huckans M, Morasco BJ Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010, 37:519-533.
42. Sharpley CF, Agnew LL Cytokines and depression: findings, issues, and treatment implications. Rev Neurosci 2011, 22:295-302.
43. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 2010, 59:1394-1400.
44. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998, 113:401-406.
45. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997, 94:3195-3199.
46. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor [alpha]. Clin Neuropharmacol July 2010, 33(4):191-197.
47. Kupper N, Widdershoven JW, Pedersen SS Cognitive/affective and somatic/affective symptom dimensions of depression are associated with current and future inflammation in heart failure patients. J Affect Disord 2012, 136:567-576.
48. Hennings A, Zill P, Rief W Serotonin transporter gene promoter polymorphism and somatoform symptoms. J Clin Psychiatry 2009, 70:1536-1539.
49. Beevers CG, Wells TT, McGeary JE The BDNF Val66Met polymorphism is associated with rumination in healthy adults. Emotion 2009, 9:579-584.
50. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
51. Kurian BT, Greer TL, Trivedi MH Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 2009, 9:975-984.
52. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35:704-708.
53. Karaivazoglou K, Iconomou G, Triantos C, Hyphantis T, Thomopoulos K, Lagadinou M, et al. Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Ann Hepatol 2010, 9:419-427.
54. Hauser P, Morasco BJ, Linke A, Bjornson D, Ruimy S, Matthews A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics 2009, 50:500-505.
55. Loftis JM, Matthews AM, Hauser P Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 2006, 66:155-174.
56. Sylvestre DL, Zweben JE Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007, 18:406-410.
57. Hofmann WP, Zeuzem S A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011, 8:257-264.